Fig. 2: The IKK complex and PKC function in PFKL Ser775 phosphorylation.

Immunoblot analysis of indicated proteins. mBMDM were pretreated with DMSO, Takinib (+, 50 µM; ++, 100 µM) (a), TPCA-1 ( +, 5 µM; ++, 10 µM) (b), Wortmannin (+, 10 µM; ++, 20 µM) (c), or MK2206 2HCl (+, 10 µM; ++, 20 µM) (d) for 1 h and then stimulated with R848 (1 µg/ml) for the indicated time periods. hMDM were pretreated with DMSO, Takinib (1, 5, 10 and 20 µM) (e), TPCA-1 (1, 5, 10 and 20 µM) (f), or Wortmannin (1, 5, 10 and 20 µM) (g) for 1 h and then stimulated with R848 (1 µg/ml) for 1 h. h, i mBMDM, primed with 20 ng/ml mouse IFNγ overnight, were pretreated with DMSO, TPCA-1 ( + , 1 µM; ++, 5 µM), or Takinib (+, 1 µM; ++, 5 µM) (h), or Go 6983 (0.1, 1, 5 and 10 µM) (i) for 1 h and then stimulated with zymosan (100 µg/ml) for 1 h. j PFKL Ser775 phosphorylation and total PFKL levels were analyzed using western blot after the in vitro kinase assay. a–j are representative of three independent experiments. Source data are provided as a Source Data file.